Laurus Labs Ltd Company History

Set up the R&D Centre

Signed term sheet with a leading Indian pharmaceutical company for oncology APIs

Filed the first patent application

Set up Unit 1

Investment by Aptuit Singapore of Rs.1.02 billion in the Company

Executed manufacturing and services agreements with three multinational companies

Commenced operations at the R&D Centre

Filed first Drug Master File

Commenced operations at Unit 1

Supplied the Company’s first product to the USA

DSIR recognition received for the R&D Centre

Commercialised four nutritional fine chemicals

Launched the Company’s first product in Europe

Entered into a license agreement with an international organization and a multinational company for license to manufacture and sell one of the products in the ARV segment

Received US FDA certification, TGA and UK MHRA certification for the Unit 1

Received US FDA certification for the R&D Centre

Received Korean FDA certification for Unit 1 and the R&D Centre

Investment of Rs.490 million in the Company by FIL Capital Management and FIP through primary investment and secondary acquisition of Aptuit’s majority stake in the Company along with additional investments by one of the Promoters

Script Award for the Best Company in an Emerging Market”

FAPCCI (The Federation of Andhra Pradesh Chambers of Commerce and Industry) Award for Outstanding Export Performance” (Silver Rolling Trophy)

Outstanding Exports Performance Award” - Bulk Drugs (medium) - Gold by Pharmaceuticals Export Promotion Council of India (PHARMEXCIL”)

Crossed Rs.10 billion of revenues

Received WHO approval for Unit 1

Purchased/ leased land at Visakhapatnam for future expansion

Outstanding Exports Performance Award – Bulk Drugs - Silver by PHARMEXCIL

Silver Certificate of Merit at the Economic Times India Manufacturing Excellence Awards, 2013

Purchased approximately 135 acres of land at Visakhapatnam for future expansion

Investment of Rs.3,000 million by Bluewater and acquisition by Bluewater of significant stake from FIL Capital Management and FIP (acting through FIL Capital Advisors) through secondary share purchase transaction

Commenced construction of Unit 2

Incorporated Laurus Inc. at Delaware as a wholly owned subsidiary of the Company

Vishwakarma Rashtriya Puraskar and National Safety Award for Unit 1, presented by the Ministry of Labour and Employment, Government of India for the performance year 2012

Outstanding Exports Performance Award- Bulk Drugs (Mid Range) by PHARMEXCIL

Silver Certificate of Merit at the Economic Times India Manufacturing Excellence Awards, 2014

‘Excellence in Performance & Business Scalability (Large Companies)’ award, in the Business Today-YES Bank Emerging Companies Excellence Awards

Commenced commercial operations at Unit 3

Acquired 27% stake in Sriam Labs

Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites

The Company was featured as one of the 13 Hidden Gems in India by Forbes India and the CEO was featured on its cover page

‘Health Care Company of the Year 2015’ award by VC Circle

Silver Certificate of Merit at the India Manufacturing Excellence Awards, 2015

‘Best Visualised App Delivery Implementation’ award from Citrix

Certificate of achievement in the Business Leader 2015 Award for excellence in the pharmaceuticals sector

Successful US FDA inspection of the kilo lab facility at R&D Hyderabad

Received approval from BfraM Germany for Unit 2

Crossed Rs.15 billion in revenues

Filed first ANDA with the US FDA and first dossier with the WHO

Acquired balance 73% stake in Sriam Labs, making it a wholly owned subsidiary of the Company

National Safety Award (runner-up) for Unit 1, presented by the Ministry of Labour and Employment, Government of India for the performance year 2014

Laurus Labs Limited today received Establishment Inspection Report (EIR) from the US Food and Drug Administration(USFDA) for its API (active pharma ingredients) plants located at Visakhapatnam in Andhra Pradesh.

Laurus Labs Ltd has received its maiden tentative approval from United States Food and Drug Administration (U.S FDA) for Tenofovir Disoproxil Fumarate Tablets 300mg.

Laurus Labs bags approval for Metformin Hydrochloride Tablets.

Laurus Labs Certified As The Great Place To Work” In The Large Sized Organisationcategory In India.

Laurus Labs got Metformin USFDA Approval.

Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa.

Lauras Labs got USFDA Approval for TLD Tablets and EIR from USFDA.

Laurus Labs enters into strategic partnership agreement with the Global Fund.

Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam.

Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market.

Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States.

Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers.

Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.

Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance.

Press Release- Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO.

Laurus Labs Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children.

Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication.

'Laurus Labs Receipt of purchase orders from a leading Global Life Sciences Company''.

Laurus Labs received USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment.

Laurus Labs signed Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets.